JP2007530529A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007530529A5 JP2007530529A5 JP2007504560A JP2007504560A JP2007530529A5 JP 2007530529 A5 JP2007530529 A5 JP 2007530529A5 JP 2007504560 A JP2007504560 A JP 2007504560A JP 2007504560 A JP2007504560 A JP 2007504560A JP 2007530529 A5 JP2007530529 A5 JP 2007530529A5
- Authority
- JP
- Japan
- Prior art keywords
- residue
- disorder
- psychotropic drug
- chemical
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000126 substance Substances 0.000 claims 44
- 229940001470 psychoactive drug Drugs 0.000 claims 37
- 239000004089 psychotropic agent Substances 0.000 claims 37
- 150000007524 organic acids Chemical group 0.000 claims 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 20
- 238000000034 method Methods 0.000 claims 16
- 201000010099 disease Diseases 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 230000001028 anti-proliverative effect Effects 0.000 claims 9
- 125000004432 carbon atom Chemical group C* 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 8
- 230000003034 chemosensitisation Effects 0.000 claims 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 239000002253 acid Substances 0.000 claims 5
- 208000015114 central nervous system disease Diseases 0.000 claims 5
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 5
- 230000002062 proliferating effect Effects 0.000 claims 5
- 208000019022 Mood disease Diseases 0.000 claims 4
- 230000000202 analgesic effect Effects 0.000 claims 4
- 239000000935 antidepressant agent Substances 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 229940127089 cytotoxic agent Drugs 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 239000003640 drug residue Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 3
- 150000001263 acyl chlorides Chemical class 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 239000001961 anticonvulsive agent Substances 0.000 claims 3
- 239000000939 antiparkinson agent Substances 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 claims 3
- 208000020016 psychiatric disease Diseases 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 239000011593 sulfur Substances 0.000 claims 3
- 239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 claims 2
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical group OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 claims 2
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims 2
- 208000017194 Affective disease Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical group CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 2
- 206010034010 Parkinsonism Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical group CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 230000001430 anti-depressive effect Effects 0.000 claims 2
- 230000000648 anti-parkinson Effects 0.000 claims 2
- 230000000561 anti-psychotic effect Effects 0.000 claims 2
- 229940005513 antidepressants Drugs 0.000 claims 2
- 239000002249 anxiolytic agent Substances 0.000 claims 2
- 230000009286 beneficial effect Effects 0.000 claims 2
- 125000003310 benzodiazepinyl group Chemical group N1N=C(C=CC2=C1C=CC=C2)* 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 2
- 208000018459 dissociative disease Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 239000002899 monoamine oxidase inhibitor Substances 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000022821 personality disease Diseases 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- 230000002194 synthesizing effect Effects 0.000 claims 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical group C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical group O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims 1
- 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 claims 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical group C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical group CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
- 206010059282 Metastases to central nervous system Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical group C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 claims 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical group N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 230000001773 anti-convulsant effect Effects 0.000 claims 1
- 229940035678 anti-parkinson drug Drugs 0.000 claims 1
- 229960003965 antiepileptics Drugs 0.000 claims 1
- FFSAXUULYPJSKH-UHFFFAOYSA-N butyrophenone Chemical group CCCC(=O)C1=CC=CC=C1 FFSAXUULYPJSKH-UHFFFAOYSA-N 0.000 claims 1
- -1 chloroalkyl ester Chemical class 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 229960002464 fluoxetine Drugs 0.000 claims 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical group COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N fumaric acid group Chemical group C(\C=C\C(=O)O)(=O)O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical group NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid group Chemical group C(CCCC(=O)O)(=O)O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 229960001680 ibuprofen Drugs 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 229960002296 paroxetine Drugs 0.000 claims 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N pentanoic acid group Chemical group C(CCCC)(=O)O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid group Chemical group C(C=1C(C(=O)O)=CC=CC1)(=O)O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 229940124811 psychiatric drug Drugs 0.000 claims 1
- 230000000506 psychotropic effect Effects 0.000 claims 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N retinoic acid group Chemical group C\C(=C/C(=O)O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims 1
- 229960002073 sertraline Drugs 0.000 claims 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical group C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid group Chemical group C(CCC(=O)O)(=O)O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 150000003573 thiols Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/808,541 US7544681B2 (en) | 2001-09-27 | 2004-03-25 | Conjugated psychotropic drugs and uses thereof |
| US10/808,541 | 2004-03-25 | ||
| PCT/IL2005/000341 WO2005092392A2 (en) | 2004-03-25 | 2005-03-27 | Conjugated psychotropic drugs and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011020274A Division JP2011121971A (ja) | 2004-03-25 | 2011-02-02 | コンジュゲート化された向精神性薬物およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007530529A JP2007530529A (ja) | 2007-11-01 |
| JP2007530529A5 true JP2007530529A5 (https=) | 2008-02-21 |
| JP5038126B2 JP5038126B2 (ja) | 2012-10-03 |
Family
ID=34966838
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007504560A Expired - Fee Related JP5038126B2 (ja) | 2004-03-25 | 2005-03-27 | コンジュゲート化された向精神性薬物およびその使用 |
| JP2011020274A Pending JP2011121971A (ja) | 2004-03-25 | 2011-02-02 | コンジュゲート化された向精神性薬物およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011020274A Pending JP2011121971A (ja) | 2004-03-25 | 2011-02-02 | コンジュゲート化された向精神性薬物およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (8) | US7544681B2 (https=) |
| EP (1) | EP1727566A2 (https=) |
| JP (2) | JP5038126B2 (https=) |
| CN (1) | CN1997400A (https=) |
| CA (1) | CA2560905A1 (https=) |
| MX (1) | MXPA06010924A (https=) |
| WO (1) | WO2005092392A2 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7544681B2 (en) * | 2001-09-27 | 2009-06-09 | Ramot At Tel Aviv University Ltd. | Conjugated psychotropic drugs and uses thereof |
| NZ527142A (en) | 2003-07-23 | 2006-03-31 | Douglas Pharmaceuticals Ltd | A stable suspension formulation |
| US20050171088A1 (en) * | 2004-01-30 | 2005-08-04 | Astrazeneca Ab | Treatment of psychoses with dibenzothiazepine antipsychotic |
| US7402652B2 (en) | 2004-09-14 | 2008-07-22 | Miller Landon C G | Baclofen conjugate and a pharmaceutical composition for treatment of neuronal disorders |
| EP2272537A3 (en) | 2005-06-07 | 2014-10-22 | Ramot at Tel-Aviv University Ltd. | Salts of conjugated psychotropic drugs and processes of preparing same |
| JP5284779B2 (ja) * | 2005-06-07 | 2013-09-11 | ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド | コンジュゲート化された向精神薬の新規な塩およびその調製方法 |
| JP5163986B2 (ja) * | 2005-09-23 | 2013-03-13 | エスケー バイオファーマスティカルズ カンパニー リミテッド | フェニル酪酸ナトリウムを使用する、薬物依存症又はアルコール依存症或いは躁うつ病の予防又は治療のための医薬組成物 |
| WO2007079470A2 (en) | 2006-01-03 | 2007-07-12 | Algebra, Inc. | Therapeutic amine-arylsulfonamide conjugate compounds |
| EP2051735B1 (en) * | 2006-07-17 | 2012-08-29 | Ramot, at Tel Aviv University Ltd. | Conjugates comprising a psychotropic drug or a gaba agonist and an organic acid and their use treating pain and other cns disorders |
| PT103884A (pt) * | 2006-11-17 | 2008-05-19 | Astrazeneca Ab | Composições de libertação prolongada e métodos para a sua preparação |
| WO2008121859A1 (en) * | 2007-03-30 | 2008-10-09 | Xenon Pharmaceuticals Inc. | Methods of using tricyclic compounds in treating sodium channel-mediated diseases or conditions |
| WO2009101616A1 (en) | 2008-02-11 | 2009-08-20 | Ramot At Tel Aviv University Ltd. | Novel conjugates for treating neurodegenerative diseases and disorders |
| MX2010014203A (es) | 2008-06-20 | 2011-02-22 | Astrazeneca Ab | Derivados de dibenzotiazepina y sus usos - 424. |
| CN105330603A (zh) * | 2008-10-08 | 2016-02-17 | 凯飞药业公司 | Gaba偶联物及其使用方法 |
| EP2246349A1 (en) * | 2009-04-20 | 2010-11-03 | BKG Pharma ApS | Treatment of infectious diseases |
| WO2011070579A1 (en) * | 2009-12-09 | 2011-06-16 | Biolinerx Ltd. | Methods of improving cognitive functions |
| CN107714703A (zh) | 2009-12-31 | 2018-02-23 | 凯姆制药公司 | 喹硫平的氨基酸缀合物、其制备和使用方法 |
| US8377929B2 (en) * | 2010-02-24 | 2013-02-19 | Ramot At Tel-Aviv University Ltd. | Crystalline forms of the tri-mesylate salt of perphenazine-GABA and process of producing the same |
| EP3476218A1 (en) * | 2010-03-11 | 2019-05-01 | Kempharm, Inc. | Fatty acid conjugates of quetiapine, process for making and using the same |
| WO2012038963A1 (en) | 2010-09-22 | 2012-03-29 | Ramot At Tel-Aviv University Ltd. | An acid addition salt of a nortriptyline-gaba conjugate and a process of preparing same |
| CA2872976A1 (en) * | 2012-05-08 | 2013-11-14 | Cellixbio Private Limited | Compositions and methods for the treatment of neurological disorders |
| CN105106230A (zh) * | 2015-08-16 | 2015-12-02 | 南京华宽信息咨询中心 | 一种单胺氧化酶mao抑制剂及其应用 |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| AU2018378348B2 (en) | 2017-12-05 | 2024-09-19 | Sunovion Pharmaceuticals Inc. | Crystal forms and production methods thereof |
| CA3084953A1 (en) | 2017-12-05 | 2019-06-13 | Sunovion Pharmaceuticals Inc. | Nonracemic mixtures and uses thereof |
| KR20220009954A (ko) | 2019-04-17 | 2022-01-25 | 컴퍼스 패쓰파인더 리미티드 | 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법 |
| AU2020286441A1 (en) | 2019-06-04 | 2022-01-06 | Sunovion Pharmaceuticals Inc. | Modified release formulations and uses thereof |
| CN111329865A (zh) * | 2020-03-30 | 2020-06-26 | 华东理工大学 | 奋乃静在制备治疗子宫内膜癌的药物中的应用 |
| CN116808231B (zh) * | 2023-07-07 | 2024-03-26 | 中国药科大学 | 一种细胞穿膜肽偶联舒必利前药体系以及制备方法和应用 |
| CN121622600A (zh) * | 2026-02-02 | 2026-03-10 | 养系列(山东)生物科技有限公司 | 一种治疗神经衰弱的组合物及其制备方法和应用 |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2944053A (en) * | 1960-07-05 | Uiiilcu | ||
| US3058979A (en) * | 1957-05-13 | 1962-10-16 | Smith Kline French Lab | New perfluoroalkylphenothiazine derivatives |
| US2914528A (en) * | 1958-04-16 | 1959-11-24 | Smith Kline French Lab | Substituted phenothiazinyl trifluoro-methyl sulfones |
| NL227699A (https=) * | 1957-09-11 | 1900-01-01 | ||
| NL230847A (https=) * | 1957-09-25 | 1900-01-01 | ||
| US2969359A (en) * | 1958-03-24 | 1961-01-24 | Rohm & Haas | Aminoketones |
| US2969358A (en) * | 1958-12-08 | 1961-01-24 | Searle & Co | 2-chloro-10-phenothiazinecarbonylpiperazines |
| GB1460713A (en) * | 1973-06-08 | 1977-01-06 | Kefalas As | 7-fluoro substituted phenothiazines method for preparation thereof and compositions bladed rotor for a gas turbine engine |
| US3947579A (en) | 1974-06-03 | 1976-03-30 | Nelson Research & Development Company | Method and composition for potentiating neuroleptic drugs |
| US3978216A (en) | 1974-06-03 | 1976-08-31 | Nelson Research & Development Company | Method for treating schizophrenia and method and composition for potentiating neuroleptic drugs |
| US3956493A (en) * | 1974-10-21 | 1976-05-11 | E. R. Squibb & Sons, Inc. | Long acting tranquilizing agent |
| GB1540842A (en) * | 1976-08-25 | 1979-02-14 | Kefalas As | Phenothiazines |
| US5525727A (en) * | 1982-05-18 | 1996-06-11 | University Of Florida | Brain-specific drug delivery |
| JPS6072868A (ja) | 1982-10-04 | 1985-04-24 | Fujisawa Pharmaceut Co Ltd | 縮合複素環誘導体およびその製造法 |
| US4629691A (en) * | 1983-08-01 | 1986-12-16 | Syntex (U.S.A.) Inc. | Tricyclic antidepressant conjugates with antigens and enzymes |
| GB8413605D0 (en) | 1984-05-29 | 1984-07-04 | Gersan Ets | Examining unfinished gemstone |
| US5051448A (en) * | 1984-07-24 | 1991-09-24 | The Mclean Hospital Corporation | GABA esters and GABA analog esters |
| US4818936A (en) | 1985-02-15 | 1989-04-04 | The Broken Hill Proprietary Company Limited | Method and apparatus for identifying and classifying steels |
| WO1986004991A1 (en) | 1985-02-15 | 1986-08-28 | The Broken Hill Proprietary Company Limited | Classification of steel |
| GB8608335D0 (en) | 1986-04-04 | 1986-05-08 | Pfizer Ltd | Pharmaceutically acceptable salts |
| ES8707175A1 (es) * | 1986-06-13 | 1987-07-16 | Inke Sa | Procedimiento para la obtencion de la n-metil-3-(p-trifluorometilfenoxi)-3-fenilpropilamina |
| US5994392A (en) * | 1988-02-26 | 1999-11-30 | Neuromedica, Inc. | Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid |
| US5420105A (en) * | 1988-09-23 | 1995-05-30 | Gustavson; Linda M. | Polymeric carriers for non-covalent drug conjugation |
| US5104858A (en) | 1988-09-29 | 1992-04-14 | Yale University | Sensitizing multidrug resistant cells to antitumor agents |
| JPH02128564A (ja) | 1988-11-08 | 1990-05-16 | Nec Corp | 電話付きパーソナルコンピュータ |
| JP2801648B2 (ja) | 1989-06-14 | 1998-09-21 | 日本化薬株式会社 | ６―フルオロ―４―クロマノン―２―カルボン酸アミド又はエステルの製造法 |
| US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| AU3244793A (en) | 1991-12-09 | 1993-07-19 | Gem International Network, Inc. | Computer imaging system for gemstones |
| JPH0672868A (ja) | 1992-08-26 | 1994-03-15 | Maruha Corp | 抗精神病薬 |
| US5780590A (en) | 1993-10-15 | 1998-07-14 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides |
| CA2176140A1 (en) * | 1993-11-24 | 1995-06-01 | Meng Hsin Chen | Indolyl group containing compounds and the use thereof to promote the release of growth hormone(s) |
| US5534522A (en) | 1995-06-07 | 1996-07-09 | Warner-Lambert Company | (R)-(Z)-1-azabicyclo [2.2.1] heptan-3-one,O-[3-(3-methoxyphenyl)-2-propynyl] oxime maleate as a pharmaceutical agent |
| US5952365A (en) | 1995-07-13 | 1999-09-14 | Anormed Inc. | 2- 2-(Dimethylamino)ethyl!-8,8-dipropyl-2-azaspiro 4.5!decane dimaleate |
| CA2162532C (en) | 1995-11-09 | 2001-01-30 | Dana J. Vanier | Gemstone registration system |
| US5795909A (en) * | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
| DE19622489A1 (de) | 1996-06-05 | 1997-12-11 | Hoechst Ag | Salze des 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4- methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3- phenyl-propionsäure-ethylesters |
| US5966673A (en) | 1997-01-10 | 1999-10-12 | Diamond Technologies, Inc. | System and method for computerized evaluation of gemstones |
| US6130221A (en) | 1997-03-05 | 2000-10-10 | Nymox Corporation | Pharmaceutical agents that impede the initiation and progression of primary and secondary DMS disruptions |
| US6197764B1 (en) * | 1997-11-26 | 2001-03-06 | Protarga, Inc. | Clozapine compositions and uses thereof |
| US6020954A (en) | 1997-12-18 | 2000-02-01 | Imagestatistics, Inc. | Method and associated apparatus for the standardized grading of gemstones |
| US5983238A (en) | 1997-12-26 | 1999-11-09 | Diamond Id | Gemstons identification tracking and recovery system |
| JP4002006B2 (ja) | 1998-06-29 | 2007-10-31 | 日本電信電話株式会社 | 色校正装置、色校正方法、および色校正プログラムを記録した記録媒体 |
| US20010024532A1 (en) | 1998-09-21 | 2001-09-27 | Malnekoff Peter J. | Automated gemstone evaluation system |
| US6304853B1 (en) | 1998-09-21 | 2001-10-16 | Peter J. Malnekoff | Automated gemstone evaluation system |
| IL134664A0 (en) | 1999-10-29 | 2001-04-30 | Diamond And Jewelry 4 U Ltd | System for trade in precious gemstones |
| US6381510B1 (en) | 1999-11-19 | 2002-04-30 | Eruggallery.Com | Methods and apparatus for facilitating electronic commerce in area rugs |
| CA2475026A1 (en) | 1999-12-01 | 2001-06-07 | Ucb, S.A. | A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders |
| GB2379536A (en) | 2000-05-23 | 2003-03-12 | David W Hendry Jr | System and method for appraising and describing jewelry and other valuable items |
| US20020021439A1 (en) | 2000-08-07 | 2002-02-21 | Derek Priestley | Colour matching system |
| US7251619B2 (en) | 2000-09-01 | 2007-07-31 | Garry Ian Holloway | Computer implemented method, computer program product, and system for gem evaluation |
| JP2005097120A (ja) | 2000-10-06 | 2005-04-14 | Mochida Pharmaceut Co Ltd | ４−ヒドロキシピペリジン誘導体の非潮解性塩 |
| WO2002028881A1 (en) | 2000-10-06 | 2002-04-11 | Xenoport, Inc. | Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration |
| US6569853B1 (en) * | 2000-11-06 | 2003-05-27 | Combinatorx, Incorporated | Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders |
| IL139975A0 (en) | 2000-11-29 | 2002-02-10 | Univ Ramot | Anti proliferative drugs |
| US20030065586A1 (en) | 2001-07-31 | 2003-04-03 | Shaftel Keith L. | Electronic commerce product pricing and selection system and method |
| US20030115079A1 (en) | 2001-08-30 | 2003-06-19 | Rapaport Martin M. | Method of and system for ranking optimal values |
| US7544681B2 (en) | 2001-09-27 | 2009-06-09 | Ramot At Tel Aviv University Ltd. | Conjugated psychotropic drugs and uses thereof |
| JP4521187B2 (ja) | 2001-09-27 | 2010-08-11 | ラモト アット テル アヴィヴ ユニヴァーシティ リミテッド | コンジュゲートされた抗精神病薬およびこれらの使用 |
| US7005138B2 (en) | 2001-12-21 | 2006-02-28 | Duramed Pharmaceuticals, Inc. | Method of systematically delivering SSRIs |
| EP1471909A4 (en) * | 2002-01-16 | 2007-07-25 | Endo Pharmaceuticals Inc | PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM |
| EP1500010A4 (en) | 2002-01-25 | 2005-04-27 | Menahem Sevdermish | METHOD FOR THE DIGITAL COLOR GRADING OF JEWELS AND COMMUNICATION THEREFOR |
| US8046274B2 (en) | 2002-01-25 | 2011-10-25 | Menahem Sevdermish | Method for digital color grading of gems and communication thereof |
| US20040092504A1 (en) * | 2002-11-12 | 2004-05-13 | Anuthep Benja-Athon | Definitive medications for treating fibromyalgia |
| EP1675555A4 (en) | 2003-09-30 | 2011-03-09 | Shire Llc | PHARMACEUTICAL COMPOSITIONS FOR PREVENTING EXCESSIVE DOSE OR ABUSE |
| TW200616604A (en) * | 2004-08-26 | 2006-06-01 | Nicholas Piramal India Ltd | Nitric oxide releasing prodrugs containing bio-cleavable linker |
| AR054181A1 (es) | 2004-08-26 | 2007-06-06 | Nicholas Piramal India Ltd | Prodrogas que contienen enlaces bio-divisibles. composiiciones farmaceuticas |
| US7074775B2 (en) * | 2004-09-14 | 2006-07-11 | Miller Landon C G | Aminobutyramide conjugate and a pharmaceutical composition for treatment of neuronal disorders |
| US7151084B2 (en) * | 2004-12-27 | 2006-12-19 | Miller Landon C G | Compound and method of treating neurogenic conditions using non-steroidal anti-inflammatory drug complexes |
| TW200715156A (en) | 2004-11-24 | 2007-04-16 | Interdigital Tech Corp | Intelligent information dissemination using a dynamic profile |
| JP5284779B2 (ja) | 2005-06-07 | 2013-09-11 | ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド | コンジュゲート化された向精神薬の新規な塩およびその調製方法 |
| WO2007050318A2 (en) | 2005-10-24 | 2007-05-03 | Duke University | Lipidomics approaches for central nervous system disorders |
| TWI378091B (en) * | 2006-03-09 | 2012-12-01 | Eisai R&D Man Co Ltd | Multi-cyclic cinnamide derivatives |
| ES2573733T3 (es) | 2006-05-22 | 2016-06-09 | The Board Of Trustees Of The Leland Stanford Junior University | Tratamiento farmacológico del deterioro cognitivo |
| EP2051735B1 (en) | 2006-07-17 | 2012-08-29 | Ramot, at Tel Aviv University Ltd. | Conjugates comprising a psychotropic drug or a gaba agonist and an organic acid and their use treating pain and other cns disorders |
| EP2250148B1 (en) * | 2008-01-25 | 2016-08-17 | XenoPort, Inc. | Crystalline form of calcium-salts of (3s)-aminomethyl-5-methyl-hexanoic acids and methods of use |
| WO2009101616A1 (en) | 2008-02-11 | 2009-08-20 | Ramot At Tel Aviv University Ltd. | Novel conjugates for treating neurodegenerative diseases and disorders |
| US8377929B2 (en) * | 2010-02-24 | 2013-02-19 | Ramot At Tel-Aviv University Ltd. | Crystalline forms of the tri-mesylate salt of perphenazine-GABA and process of producing the same |
-
2004
- 2004-03-25 US US10/808,541 patent/US7544681B2/en not_active Expired - Fee Related
-
2005
- 2005-03-27 MX MXPA06010924A patent/MXPA06010924A/es active IP Right Grant
- 2005-03-27 CN CNA2005800170251A patent/CN1997400A/zh active Pending
- 2005-03-27 WO PCT/IL2005/000341 patent/WO2005092392A2/en not_active Ceased
- 2005-03-27 JP JP2007504560A patent/JP5038126B2/ja not_active Expired - Fee Related
- 2005-03-27 CA CA002560905A patent/CA2560905A1/en not_active Abandoned
- 2005-03-27 EP EP05718914A patent/EP1727566A2/en not_active Withdrawn
-
2006
- 2006-12-11 US US11/636,599 patent/US7619006B2/en not_active Expired - Fee Related
- 2006-12-11 US US11/636,594 patent/US20070099977A1/en not_active Abandoned
-
2007
- 2007-12-27 US US12/005,342 patent/US7598239B2/en not_active Expired - Fee Related
-
2009
- 2009-09-01 US US12/585,021 patent/US7939525B2/en not_active Expired - Fee Related
-
2010
- 2010-01-14 US US12/656,048 patent/US8283381B2/en not_active Expired - Fee Related
- 2010-04-21 US US12/764,124 patent/US8168628B2/en not_active Expired - Fee Related
-
2011
- 2011-02-02 JP JP2011020274A patent/JP2011121971A/ja active Pending
-
2012
- 2012-08-16 US US13/586,913 patent/US20120309748A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007530529A5 (https=) | ||
| WO2012115695A1 (en) | Bis-fatty acid conjugates and their uses | |
| JP5192485B2 (ja) | 向精神性薬物またはｇａｂａアゴニストと有機酸とを含むコンジュゲート、ならびに疼痛および他のｃｎｓ障害を治療するためのそれらの使用 | |
| JP2009543858A5 (https=) | ||
| JP6506248B2 (ja) | 二環式鎮痛化合物 | |
| JP5038126B2 (ja) | コンジュゲート化された向精神性薬物およびその使用 | |
| WO2011106688A1 (en) | Bis-fatty acid conjugates and their uses | |
| JP2005503423A5 (https=) | ||
| JP2011505405A5 (https=) | ||
| JP2019108376A (ja) | ヒストンアセチルトランスフェラーゼ活性剤の使用 | |
| DeRuiter et al. | Synthesis and in vitro aldose reductase inhibitory activity of compounds containing an N-acylglycine moiety | |
| CA2119662C (fr) | Nouveaux derives bicycliques azotes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| US9216224B2 (en) | Fatty acid COX inhibitor derivatives and their uses | |
| JP5284779B2 (ja) | コンジュゲート化された向精神薬の新規な塩およびその調製方法 | |
| FR2742149A1 (fr) | Nouveaux derives de 2-naphtamides et leurs applications therapeutiques | |
| JP2008545777A5 (https=) | ||
| US20110082202A1 (en) | Fatty acid acifran derivatives and their uses | |
| US20170073305A1 (en) | Fatty acid amides, compositions and methods of use | |
| CN1819822A (zh) | 含有取代喹啉和取代二苯砜的组合物以及使用方法 | |
| CN108348775B (zh) | 芬坎法明的前药 | |
| KR20260025885A (ko) | D-암페타민 화합물, 조성물, 및 그의 제조 및 사용 방법 | |
| CN101247837B (zh) | 新的轭合精神活性药物的盐及其制备方法 | |
| CN101677546A (zh) | 具有中枢神经系统活性的取代的吡咯烷化合物 |